Immunogenicity and safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3–18 years old: a double-blinded, multicentre, randomised, phase 1/2 clinical trial (ISMAELILLO study)

BACKGROUND: COVID-19 in paediatric ages could result in hospitalizations and death. In addition, excluding children from vaccination could turn them into reservoirs of the SARS-COV-2. Safe and effective COVID-19 vaccines are urgently needed for large-scale paediatric vaccination. ISMAELILLO study ai...

Descripción completa

Detalles Bibliográficos
Autores principales: Cinza-Estévez, Zurina, Resik-Aguirre, Sonia, Figueroa-Baile, Nelvis L., Oquendo-Martínez, Rachel, Campa-Legrá, Ivan, Tejeda-Fuentes, Alina, Rivero-Caballero, Marila, González-García, Gloria, Chávez-Chong, Cristina O., Alonso-Valdés, Marel, Hernández-Bernal, Francisco, Lemos-Pérez, Gilda, Campal-Espinosa, Ana, Freyre-Corrales, Giselle, Benítez-Gordillo, Delia, Gato-Orozco, Evelyn, Pérez Bartutis, Greter Susana, Mesa-Pedroso, Iliana, Bueno-Alemani, Nilda, Infante-Aguilar, Elizabeth, Rodríguez Reinoso, José Luis, Melo-Suarez, Grettel, Limonta-Fernández, Miladys, Ayala-Ávila, Marta, Muzio-González, Verena L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462868/
https://www.ncbi.nlm.nih.gov/pubmed/37649806
http://dx.doi.org/10.1016/j.eclinm.2023.102160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462868/
https://www.ncbi.nlm.nih.gov/pubmed/37649806
http://dx.doi.org/10.1016/j.eclinm.2023.102160

Ejemplares similares